Haemonetics Co. (NYSE:HAE - Get Free Report)'s stock price hit a new 52-week low on Monday . The company traded as low as $58.24 and last traded at $59.18, with a volume of 244221 shares. The stock had previously closed at $60.88.
Analyst Upgrades and Downgrades
HAE has been the topic of several research reports. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. JMP Securities cut their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reduced their target price on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $101.22.
Check Out Our Latest Analysis on HAE
Haemonetics Stock Up 1.2 %
The business has a fifty day moving average price of $63.60 and a two-hundred day moving average price of $73.46. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company has a market cap of $3.01 billion, a price-to-earnings ratio of 23.61, a P/E/G ratio of 1.11 and a beta of 0.41.
Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter valued at about $25,000. Covestor Ltd lifted its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after acquiring an additional 439 shares during the last quarter. Whittier Trust Co. bought a new stake in Haemonetics in the fourth quarter worth approximately $62,000. Parkside Financial Bank & Trust increased its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares during the last quarter. Finally, AlphaQuest LLC raised its holdings in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after purchasing an additional 1,826 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
